Palisade Bio, Inc. (PALI)

Over the past six months, Palisade Bio's stock has been impacted by positive clinical data from its Phase 1b study of PALI-2108 in FSCD, which showed favorable safety and tolerability. Multiple firms initiated coverage with "Buy" or "Outperform" recommendations and increased price targets. Palisade Bio entered into a master services agreement with Iterative Health and received a strategic equity investment from the Crohn's & Colitis Foundation's IBD Ventures Program. The company participated in several investor conferences. The share price as of April 8, 2026, was $1.87, representing a 165.25% increase over the past year.

Palisade Bio, Inc.'s products and services are not subject to typical demand seasonality. The demand for treatments for chronic conditions like inflammatory bowel disease is generally consistent throughout the year.

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for chronic gastrointestinal diseases, including autoimmune, inflammatory, and fibrotic conditions. Their primary product candidate is PALI-2108, a PDE4 inhibitor prodrug designed for targeted delivery to treat inflammatory bowel disease. The company is also researching PALI-1908.

Palisade Bio, Inc. is headquartered in Carlsbad, California, and Denver, Colorado, United States, with facilities in the US. Its stock is listed on NasdaqCM in the US and Deutsche Boerse AG in Germany. A significant portion of its shareholders, 81.7%, are based in the United States.

Palisade Bio's brand reputation over the past year appears to be generally positive, driven by encouraging clinical trial results and favorable analyst sentiment. The company reported positive topline data from its Phase 1b study of PALI-2108 in FSCD and presented clinical and mechanistic data at scientific conferences. This progress has led to multiple analyst firms initiating coverage with "Buy" or "Outperform" recommendations and increasing price targets. The strategic equity investment from the Crohn's & Colitis Foundation also indicates external validation.

Palisade Bio, Inc. has 89 institutional owners and shareholders holding a total of 135,910,849 shares. Major institutional owners include Perceptive Advisors Llc, Commodore Capital Lp and Janus Henderson Group Plc. Individuals hold approximately 0.03% of the shares.